As of 1 July 2019, the Technical Review Panel (TRP) has completed its reviews of funding requests for the 2017-2019 allocations and has issued recommendations covering all of the funds available for country allocation ($10.3 billion); all of the matching funds that were subject to TRP review ($313 million); and all of the funds earmarked for multi-country grants ($260 million).
On 16 August 2019, by electronic vote, the Global Fund Board approved funding for three country grants worth $32.7 million (Colombia HIV, Honduras TB/HIV and Kazakhstan TB). Domestic commitments for the programs included in the approved country grants amounted to $1.17 billion. Initiatives valued at $2.4 million were added to the Unfunded Quality Demand (UQD) Register. (See Table 1.)
On 24 July 2019, the Global Fund Board approved funding in the amount of $18.0 million from the 2017-2019 allocations for several interventions on the Unfunded Quality Demand (UQD) Register. The funds will be added to three existing country grants and one existing multi-country grant. The sources of these funds are portfolio optimization and a private sector contribution. (See Table 1 below.)
The Global Fund describes the $41.6 million in funding awarded to India in April as an innovative approach that will catalyze significant additional funding for the fight against tuberculosis. The award includes $40.0 million to buy down a portion of a $400.0-million loan from the World Bank over five years.
Global Fund Board approves new country and multi-country grants along with interventions on UQD Register
On 13 May 2019, the Global Fund Board approved, by electronic vote, funding for five country grants having a total value of $25.2 million. Domestic commitments for the programs included in the approved country grants amounted to $937.9 million. The five country grants were for four countries: Gabon, Georgia, Peru and Serbia. The largest award ($9.3 million) was for a Georgia HIV grant. (See Table 1 for details.)
New implementation arrangements have been put in place for the TB programs funded through Nigeria’s new TB and TB/HIV grants.
The Global Fund seeks the right balance between risk mitigation and grant implementation in Mali malaria grant
When it recommended a Mali malaria grant for approval recently, the Global Fund’s Grant Approvals Committee (GAC) acknowledged that there are implementation challenges associated with this grant and said that it welcomed the Secretariat’s plans “to identify bottlenecks, and holistically review and harmonize the controls in place with the aim of balancing risk mitigation and effective grant implementation.”
Among the grants approved by the Global Fund Board on 21 December 2018 (see GFO article) were three multi-country grants. Two of the grants were for Eastern Europe and Central Asia (EECA); the third was for West and Central Africa. (See table.)
Of the $98 million in country grants approved by Global Fund Board from 2017-2019 allocations, Latin America and Caribbean receive $57 million
This is the second of two articles in this issue on the grants recently approved by the Global Fund Board. In this article, we report on the comments of the Grant Approvals Committee (GAC) on four countries in the Latin American and Caribbean region: Belize, El Salvador, Panama and Paraguay.
On 12 November 2018, through electronic voting, the Global Fund Board approved $98.0 million in funding for 14 country grants from 13 countries. Of the 14 grants, four were for TB; three TB/HIV; three HIV; three malaria; and one TB/RSSH.